Nasdaq notifies ENDRA Life Sciences of delisting due to bid price; company to appeal

ENDRA Life Sciences Inc.

Stock closed below $0.10 for 10 consecutive trading days ended July 12, triggering delisting under Nasdaq Rule 5810(c)(3)(A)(iii).
Company requested hearing on July 16; hearing request automatically stays delisting pending panel decision.
At August 6 annual meeting, company will seek stockholder approval for reverse stock split at ratio between 1:20 and 1:50.
No assurance that Nasdaq panel will grant compliance period or that company will ultimately regain listing compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.